TF 2-targeted cancer therapy

N/A

Report date: 2022/09/02 15:09:05

Base Information

Drug NameTF 2-targeted cancer therapy
Drug Alias NameTF-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[5] 
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsIonising radiation emittersRadionuclide imaging enhancers +[4] 
TargetsHistamine succinyl glycineCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Colorectal NeoplasmsMastocytosis, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIbc Pharmaceuticals IncImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncNantes University HospitalJado Technologies Gmbh
Active IndicationsN/A
Inactive IndicationsMedullary thyroid cancer (MTC)Colorectal NeoplasmsMastocytosis, Cutaneous

Other Information

ATC CodeN/A
Related LinksN/A